Heart Failure

A multi-faceted screening approach could prevent sudden cardiac deaths in young athletes.

Including warning labels may improve healthy eating habits.

Americans admitted to the hospital for heart failure have a 6% higher risk of dying than patients admitted in the spring.

Treatments have only increased 10% in hospitals nationwide over the past decade.

A self-expanding transcatheter aortic valve replacement (TAVR) procedure was just as effective as surgery in intermediate risk patients.

The Patient Navigator Program reduced readmission for heart attack or heart failure patients by 81.3%.

Small case report found an association between the Zika virus and cardiovascular complications.

FOURIER trial meets its primary composite endpoint reducing cardiovascular risk factors.

Some high-risk patients have better than expected outcomes due to frequent follow-up by physicians.

Heart failure higher among RA patients independent of their risk for ischemic heart disease.

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago.

The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.

Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.

Physical inactivity and weight gain may increase the risk of heart failure with preserved ejection fraction.

A porcupine inhibitor may regenerate heart tissue after a heart attack and prevent heart failure.

Stress may increase brain activity and lead to inflammation of the heart.

A cardiac lipid panel test plus a NT-proBNP test may be able to diagnose heart failure early.

EZR-201 combines an angiotensin receptor blocker, valsartan, with Rubireten delivery technology for the treatment of hypertension and heart failure.

The FDA has accepted the new drug application (NDA) for EZR-201, an investigational product from Ezra Innovations for the treatment of hypertension and heart failure.

In this clip, Dr. Peter Salgo, a professor of medicine and anesthesiology at Columbia University College of Physicians and Surgeons; and an associate director of Surgical Intensive Care at New York-Presbyterian Hospital discusses heart failure.

The costs of generic heart failure medications can vary by hundreds of dollars.

Treatment with Entresto was associated with a reduction in hospitalization and death up to 24% in patients with heart failure.

An initiative that lowered copays for prescription drugs also lowered hospitalizations by 40%

Type 2 diabetes patients struggle with high blood glucose levels that can damage nerves and blood vessels, factors that could trigger heart attacks.

Low health literacy, financial instability, and lack of social support promote poor adherence.